Drug Trial Radar · NCT07060456
Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin
Last checked: Nov 19, 2026Latest source record: Jan 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Jul 25, 2025
Primary completion
Feb 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the efficacy and safety of HRS9531 compared with placebo in participants with type 2 diabetes mellitus not adequately controlled with basal insulin, with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study may include up to 23 visits.
Conditions
- Type 2 Diabetes
Interventions
HRS9531Drug
HRS9531-low dose
HRS9531Drug
HRS9531-high dose
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1cTime frame: from baseline to Week 40
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Perking University Peoples' Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.